4/22
04:05 pm
avbp
ArriVent Appoints Kristine Peterson to its Board of Directors
Low
Report
ArriVent Appoints Kristine Peterson to its Board of Directors
3/28
08:39 pm
avbp
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib [Yahoo! Finance]
Low
Report
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib [Yahoo! Finance]
3/28
08:30 pm
avbp
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
Low
Report
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
3/28
04:19 pm
avbp
ArriVent BioPharma Reports Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
ArriVent BioPharma Reports Full Year 2023 Financial Results [Yahoo! Finance]
3/28
04:05 pm
avbp
ArriVent BioPharma Reports Full Year 2023 Financial Results
Low
Report
ArriVent BioPharma Reports Full Year 2023 Financial Results
2/20
07:29 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $35.00 price target on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $35.00 price target on the stock.
2/20
07:17 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $30.00 price target on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $30.00 price target on the stock.
2/20
07:17 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $27.00 price target on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $27.00 price target on the stock.
2/20
07:17 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $27.00 price target on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $27.00 price target on the stock.
2/20
07:17 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $30.00 price target on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $30.00 price target on the stock.